Promising Developments and Market Potential for Kala Pharmaceuticals’ KPI-012 Amidst Clinical and Regulatory Challenges

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Kala Pharmaceuticals today and set a price target of $12.00.

Yi Chen’s rating is based on the promising developments in Kala Pharmaceuticals’ clinical trials and the potential market opportunity for their product KPI-012. The completion of patient enrollment in the Phase 2b CHASE trial for treating persistent corneal epithelial defect (PCED) marks a significant milestone, with topline data expected in the third quarter of 2025. This trial is crucial as there is currently no FDA-approved drug for PCED, which affects approximately 100,000 patients in the U.S.
Furthermore, the positive safety data from the high dose KPI-012 in the initial cohort of the Phase 2b trial supports the potential efficacy and safety of the treatment. The ongoing trial could serve as a pivotal study for a Biologics License Application if successful. The valuation of Kala Pharmaceuticals, with a price target of $12 per share, reflects a discounted cash flow analysis and considers both the potential approval and market success of KPI-012. However, risks remain, including clinical trial failure, regulatory challenges, and market competition.